Media coverage about ChemoCentryx (NASDAQ:CCXI) has been trending somewhat positive recently, according to Accern Sentiment. The research group identifies negative and positive news coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. ChemoCentryx earned a daily sentiment score of 0.19 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 46.9943121699741 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Here are some of the media headlines that may have effected Accern’s rankings:
- Edited Transcript of CCXI earnings conference call or presentation 9-Mar-18 1:30pm GMT (finance.yahoo.com)
- ChemoCentryx (CCXI) Rating Lowered to Hold at Zacks Investment Research (americanbankingnews.com)
- 52-week High Price Level To Watch- ChemoCentryx, Inc. (CCXI) – The Stocks News (press release) (thestocksnews.com)
- ChemoCentryx (CCXI) Upgraded to Buy at ValuEngine (americanbankingnews.com)
- ChemoCentryx (CCXI) Upgraded at BidaskClub (americanbankingnews.com)
ChemoCentryx stock opened at $14.14 on Monday. The company has a debt-to-equity ratio of 0.06, a current ratio of 5.46 and a quick ratio of 2.76. The firm has a market capitalization of $691.74, a PE ratio of 39.28 and a beta of 1.89. ChemoCentryx has a 1-year low of $5.42 and a 1-year high of $14.47.
ChemoCentryx (NASDAQ:CCXI) last issued its quarterly earnings results on Friday, March 9th. The biopharmaceutical company reported $0.80 EPS for the quarter, topping analysts’ consensus estimates of ($0.22) by $1.02. The company had revenue of $56.30 million during the quarter, compared to analysts’ expectations of $9.03 million. equities research analysts forecast that ChemoCentryx will post -1.18 EPS for the current year.
A number of research analysts have weighed in on CCXI shares. BidaskClub raised ChemoCentryx from a “sell” rating to a “hold” rating in a report on Wednesday, March 14th. JPMorgan Chase & Co. reissued an “overweight” rating and issued a $16.00 target price (up previously from $13.00) on shares of ChemoCentryx in a report on Tuesday, March 13th. Zacks Investment Research raised ChemoCentryx from a “hold” rating to a “buy” rating and set a $14.00 target price on the stock in a report on Wednesday, March 14th. Finally, ValuEngine raised ChemoCentryx from a “hold” rating to a “buy” rating in a report on Wednesday, March 14th. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $15.00.
ChemoCentryx, Inc is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact.
Receive News & Ratings for ChemoCentryx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx and related companies with MarketBeat.com's FREE daily email newsletter.